Neurology & DFPP:
What We Really Know
Double Filtration Plasmapheresis (DFPP) is an advanced apheresis technique that is gaining increasing attention in neurology due to its selective, safe and effective removal of pathogenic plasma components.
Below, we present a comprehensive synthesis of current knowledge on DFPP in neurological practice, based on clinical evidence, patient experience, and a mechanistic understanding of this method.
How it works
DFPP is a blood washing procedure that uses a two-stage filtration process:
- First filter: Separates plasma from blood cells.
- Second filter: Selectively removes high molecular weight substances (e.g., autoantibodies, immune complexes, certain proteins), allowing the majority of normal plasma proteins (such as albumin) to be returned to the patient’s body
Key advantages over traditional plasmapheresis
Selectivity
DFPP targets only harmful large molecules while sparing beneficial plasma proteins.
Reduced need for replacement fluids
Most of the patient's plasma is returned, minimizing the need for donor plasma or albumin and reducing the risk of transfusion-related complications.
Lower risk of side effects
Less depletion of essential proteins and fewer allergic or infectious reactions
Neurological indications for DFPP
DFPP is used for a wide range of neurological conditions, particularly those with autoimmune or inflammatory causes. Key indications include:
- Multiple sclerosis (MS): Especially in relapsing-remitting forms during severe relapses resistant to glucocorticosteroids or when standard drugs are contraindicated.
- Myasthenia gravis (pseudoparalytic myasthenia gravis): As adjunctive therapy in severe or refractory cases.
- Allergic encephalitis, slowly progressive viral infections of the central nervous system, and even Alzheimer’s disease (experimental/additional use).
- Guillain-Barré syndrome (GBS): In acute exacerbations and recurrent forms, including atypical variants.
- Chronic inflammatory demyelinating polyneuropathy (CIDP): Especially when refractory to steroids or immunoglobulin therapy.
- Neuromyelitis optica (NMO, Devic’s syndrome ): For rapid removal of antibodies against aquaporin-4 during severe relapses.
- Miller Fisher syndrome: To reduce the level of autoantibodies against gangliosides.
- Autoimmune encephalitis: Especially when it does not respond to steroids or intravenous immunoglobulins (IVIG).
- DFPP is on trial for neurological complications of infections (e.g., cytokine storms, post-COVID-19 brain fog, HCV-associated cryoglobulinemia with neuropathy).
DFPP is also being investigated in neurological complications of infection (e.g., cytokine storms, post-COVID-19 brain fog, HCV-associated cryoglobulinemia with neuropathy).
Clinical evidence and effectiveness
High response rates
Clinical improvement following DFPP treatment has been reported in approximately 80% of cases of autoimmune neuromuscular diseases, with most complications being mild and manageable.
Rapid symptom relief
DFPP can rapidly reduce levels of pathogenic antibodies and immune complexes, leading to faster recovery and reduced disability in conditions such as GBS, CIDP, NMO, and myasthenia gravis.
Comparable to TPE
DFPP achieves similar short-term outcomes and hospital stay duration to traditional plasma exchange (TPE), but with a more selective washing profile and fewer side effects.
New and experimental applications
- Alzheimer’s disease: Early research and clinical experience suggest that DFPP may help by removing pathogenic proteins (e.g., amyloid-beta, tau) and inflammatory mediators, potentially slowing cognitive decline and improving biomarker profiles. However, this is still an area of ongoing research.
- Post-infectious and inflammatory syndromes: DFPP is used to remove cytokines and immune complexes in conditions such as long-term COVID-19 with brain fog and in infectious encephalitis with immune mechanisms
Safety profile, side effects and contraindications
- Generally safe and well tolerated: Most adverse events are mild (e.g., local hematoma, mild thrombosis, transient hypotension, mild fatigue) and related to vascular access.
- No need for donor plasma: This reduces the risk of allergic reactions and transmission of infections.
- Serious complications are rare: Severe bleeding, infection, or anaphylaxis are rare.
- Absolute contraindications: Uncontrolled bleeding, severe hypotension, inability to obtain vascular access.
- Relative contraindications: Severe cardiac instability, active infection (unless DFPP is used as adjunctive therapy), severe hypoproteinemia, allergy to filter materials.
- Special Notes: Neurological patients with advanced neuromuscular weakness or autonomic dysfunction require close monitoring during the procedure.
Patient experience and practical aspects
- Recent studies: Retrospective and prospective studies support the efficacy and safety of DFPP in autoimmune encephalitis, MS, NMO, myasthenia gravis, and GBS, with significant improvements in neurological outcomes and low relapse rates.
- Ongoing Trials: Multicenter randomized trials and real-world studies are being conducted to further clarify the role of DFPP and optimize protocols for neurological applications.
Application
DFPP represents a significant advance in managingneurological diseases, particularly those with autoimmune or inflammatory mechanisms. Its selective action, favorable safety profile, and growing evidence base make it a valuable therapeutic option for both acute and chronic neurological conditions. While solid data is still being gathered, especially in emerging areas such as neurodegeneration and post-infectious syndromes, DFPP is already recognized as an effective and patient-friendly intervention for many neuroimmune disorders.
